DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Real-time Bid/Ask 17:52:27 31/05/2024 BST | ||
| 267.02 EUR / 267.34 EUR | +0.18% |
|
| Current month | -0.28% | ||
| 1 month | -0.28% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 31/05/24 | 266.9 | +0.09% |
| 30/05/24 | 266.7 | -0.31% |
| 29/05/24 | 267.5 | +0.33% |
| 28/05/24 | 266.6 | -0.15% |
| 27/05/24 | 267 | -0.04% |
Delayed Quote Börse Stuttgart
Last update May 31, 2024 at 04:02 pm
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | MG1BSZ |
| ISIN | DE000MG1BSZ2 |
| Date issued | 02/04/2024 |
| Maturity | 21/03/2025 (294 Days) |
| Parity | 1 : 1 |
| Emission price | 263.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 267.8 € |
|---|---|
| Lowest since issue | 260.4 € |
| Spread | 0.32 € |
| Spread % | 0.12% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
443
USD
Average target price
462.8
USD
Spread / Average Target
+4.46%
- Stock Market
- Certificates
- Certificat
